血管紧张素受体阻滞剂治疗高血压与癫痫风险
这项回顾性队列研究利用美国全国健康行政数据库(2010-2017年)数据,经倾向评分匹配分析高血压患者使用血管紧张素受体阻滞剂(ARB)与癫痫发病的关联。结果显示,与血管紧张素转换酶抑制剂(ACEI)、β受体阻滞剂或其他降压药联用相比,ARB使用与癫痫发病率降低相关(aHR分别为0.75、0.70、0.72)。亚组分析显示,在无卒中或心血管疾病史的患者中,ARB(主要是氯沙坦)使用与癫痫发病率存在显著关联。
要点
- ARB使用与癫痫发病率降低相关:对比ACEI的aHR为0.75,对比β受体阻滞剂的aHR为0.70,对比其他降压药联用的aHR为0.72。
- 亚组分析显示,在无卒中或心血管疾病史的患者中,ARB(主要是氯沙坦)使用与癫痫发病率存在显著关联。
- 作者认为,需要进一步研究(如随机临床试验)来确认降压药物的比较性抗癫痫发生特性。
核心结论
- 这项队列研究发现,在无卒中或心血管疾病史的高血压患者中,ARB(主要是氯沙坦)与其他降压药相比与较低的癫痫发病率相关。
- 作者认为,需要进一步研究(如随机临床试验)来确认降压药物的比较性抗癫痫发生特性。
研究设计与样本
- 这项回顾性队列研究使用2010年1月至2017年12月的全国健康行政数据库数据,并进行倾向评分匹配。
- 纳入的合格队列包括年龄18岁及以上、诊断为原发性高血压、并在2010年至2017年间至少配发1种ARB、ACEI、β受体阻滞剂或钙通道阻滞剂(CCB)的私人保险个体。
- 排除在索引日期或之前诊断为癫痫,或在开始研究药物前12个月内或后90天内配发抗癫痫药物的患者。
- 本项目的数据分析于2022年4月至2024年4月进行。
- 共纳入2 261 964例患者(平均[SD]年龄61.7[13.9]岁;1 120 630例[49.5%]女性),其中309 978例接受ARB,807 510例接受ACEI,695 887例接受β受体阻滞剂,448 589例接受CCB。
主要发现
- 倾向评分匹配后,1:1匹配的亚组包括:ARB对比ACEI组619 858例患者,ARB对比β受体阻滞剂组619 828例患者,ARB对比CCB组601 002例患者。
- 与ACEI相比,ARB使用与癫痫发病率降低相关(aHR,0.75;95%CI,0.58-0.96)。
- 与β受体阻滞剂相比,ARB使用与癫痫发病率降低相关(aHR,0.70;95%CI,0.54-0.90)。
- 与其他降压药类别联用相比,ARB使用与癫痫发病率降低相关(aHR,0.72;95%CI,0.56-0.95)。
- 亚组分析显示,在无卒中或心血管疾病史的患者中,ARB(主要是氯沙坦)使用与癫痫发病率存在显著关联。
局限性
- 作者认为,需要进一步研究(如随机临床试验)来确认降压药物的比较性抗癫痫发生特性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Animal and human studies have suggested that the use of angiotensin receptor blockers (ARBs) may be associated with a lower risk of incident epilepsy compared with other antihypertensive medications. However, observational data from the US are lacking. OBJECTIVE: To evaluate the association between ARB use and epilepsy incidence in subgroups of US patients with hypertension. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from a national health administrative database from January 2010 to December 2017 with propensity score (PS) matching. The eligible cohort included privately insured individuals aged 18 years or older with diagnosis of primary hypertension and dispensed at least 1 ARB, angiotensin-converting enzyme inhibitor (ACEI), β-blocker, or calcium channel blocker (CCB) from 2010 to 2017. Patients with a diagnosis of epilepsy at or before the index date or dispensed an antiseizure medication 12 months before or 90 days after initiating the study medications were excluded. The data analysis for this project was conducted from April 2022 to April 2024. EXPOSURES: Propensity scores were generated based on baseline covariates and used to match patients who received ARBs with those who received either ACEIs, β-blockers, CCBs, or a combination of these antihypertensive medications. MAIN OUTCOMES AND MEASURES: Cox regression analyses were used to evaluate epilepsy incidence during follow-up comparing the ARB cohort with other antihypertensive classes. Subgroup and sensitivity analyses were conducted to examine the association between ARB use and epilepsy incidence in various subgroups. RESULTS: Of 2 261 964 patients (mean [SD] age, 61.7 [13.9] years; 1 120 630 [49.5%] female) included, 309 978 received ARBs, 807 510 received ACEIs, 695 887 received β-blockers, and 448 589 received CCBs. Demographic and clinical characteristics differed across the 4 comparison groups prior to PS matching. Compared with ARB users, patients receiving ACEIs were predominantly male and had diabetes, CCB users were generally older (eg, >65 years), and β-blocker users had more comorbidities and concurrent medications. The 1:1 PS-matched subgroups included 619 858 patients for ARB vs ACEI, 619 828 patients for ARB vs β-blocker, and 601 002 patients for ARB vs CCB. Baseline characteristics were equally distributed between comparison groups after matching with propensity scores. Use of ARBs was associated with a decreased incidence of epilepsy compared with ACEIs (adjusted hazard ratio [aHR], 0.75; 95% CI, 0.58-0.96), β-blockers (aHR, 0.70; 95% CI, 0.54-0.90), and a combination of other antihypertensive classes (aHR, 0.72; 95% CI, 0.56-0.95). Subgroup analyses revealed a significant association between ARB use (primarily losartan) and epilepsy incidence in patients with no preexisting history of stroke or cardiovascular disease. CONCLUSIONS AND RELEVANCE: This cohort study found that ARBs, mainly losartan, were associated with a lower incidence of epilepsy compared with other antihypertensive agents in hypertensive patients with no preexisting stroke or cardiovascular disease. Further studies, such as randomized clinical trials, are warranted to confirm the comparative antiepileptogenic properties of antihypertensive medications.
引用
- Wen X, Otoo MN, Tang J, et al. Angiotensin Receptor Blockers for Hypertension and Risk of Epilepsy. JAMA Neurol. 2024. PMID: 38884986. doi:10.1001/jamaneurol.2024.1714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。